sugarman005, if you go to the afrezzapro website, which is a Sanofi website for Afrezza, you will see the PD for Afrezza graph from the clamp study. You will also see in the second bullet, under Study design, text about the PD. The footnote you reference reads to me like a French translation of the 2nd bullet prose whose translation does not make sense when one looks at the PD graph. Clearly the first 45 minutes PD is like insulin lispro, but after that the PD profile is nothing like lispro in the system.
It is getting more and more costly for shorts to hold anything short on MNKD. Cost yesterday was 45%. This morning I noticed it is up to 49%.
Regardless of your endo visit charles_lacey2003 is attempting to hijack charles_lacy2003 handle. charles_lacy2003 is a type 1 diabetic, and it appears charles_lacey2003 is just a visiting gnat.
lakers_w, nevertheless Lilly is advertising Jardiance very often in tv ads now. These warnings are not mentioned in the tv ads.
dekine1840, if one is a market maker who has clients who are short, it's what you do to help the client cover.
metalman_7911978, I saw the 198K puts trade for Oct $8, but 194,500 in two blocks traded for exactly $1.00 (about 11:20 am) when the bid/ask was something like .97/1.02. It looked to me it could have been a trader covering (selling as you wrote) a long put, because there was an open interest of about 213K. That's about 19 million shares that were short that some market maker covered. I assume the trader had a hefty profit he wanted to salt away.
pkgossett, it is Jewish new year, and you may have heard sell on Rosh Hashanah and buy on Yom Kippur. The shorts could play games Monday and during the week seeking advantage with assumed lower volume.
doctor.stockpicker, you are an Afrezza prescribing doctor in Oklahoma, but on Sam Finta's blog list of Afrezza prescribing docs there is no practice listed from Oklahoma. He has a lot of docs listed already all over the USA, and your practice can help with the people in Oklahoma who are looking for Afrezza.
avi8torslc, you know, you indicated in late July, as I recall, you had removed your MNKD shares from the Fido loan facility. I remember reading that. Why and when did you reup into their stock loan program?
The real doctor.stockpicker uses a dot not an underscore.
cedafuntennis, did you notice that was from the year 2005 completion. Where is the drug? Ten years should be enough time after the trial was completed.
I contacted Sanofi directly, and I asked whether Sanofi has any other inhalable drug than Afrezza. The answer I was given is Afrezza is the only inhalable drug Sanofi has. He said MNKD is developing other inhalable drugs.
I contacted Sanofi. Sanofi's only inhalable drug is Afrezza.
penny222dollar, does this change the date BAC has to return the 9 million shares MNKD loaned BAC?
blindhog1, I seem to recall you may be in some FDA trial that goes for years -- something about heart drug or something like that. Is that right? I will make the (maybe incorrect) assumption you were taking diabetic drugs before you were selected for this FDA trial. Did the FDA trial drug and procedure have any impact on your A1C at any time? Apologize if I have this FDA stuff wrong.
lakers_w, in the 8-K I see the $32.05M note matures on September 30, 2015, but the deadline for any note for stock exchange must be done between August 13,2015 and September 24, 2015.
mnholdem, yes, I understand and understood the agreement, I thought and still think. This quote from Matt Pfeffer from the earnings call is what I still have no explanation for: "Since these shares would have to be repurchased in the open market after maturity and would be returned to us,...." Thanks for posting the 2010 share lending agreement, and from the text I see nothing that would support Matt's quote above. It seems to me BAC could have had the 9M shares anytime ready to return, and there is no obligation for BAC to repurchase the 9M shares in the open market AFTER MATURITY. That quote from Matt remains a mystery to me. I have a call into Matt from yesterday to get a clarification of the statement.